281 related articles for article (PubMed ID: 22217196)
1. Effect of body mass index on treatment of complicated intra-abdominal infections in hospitalized adults: comparison of ertapenem with piperacillin-tazobactam.
Zakrison TL; Hille DA; Namias N
Surg Infect (Larchmt); 2012 Feb; 13(1):38-42. PubMed ID: 22217196
[TBL] [Abstract][Full Text] [Related]
2. Randomized, multicenter, double-blind study of efficacy, safety, and tolerability of intravenous ertapenem versus piperacillin/tazobactam in treatment of complicated intra-abdominal infections in hospitalized adults.
Namias N; Solomkin JS; Jensen EH; Tomassini JE; Abramson MA
Surg Infect (Larchmt); 2007 Feb; 8(1):15-28. PubMed ID: 17381394
[TBL] [Abstract][Full Text] [Related]
3. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial.
Solomkin JS; Yellin AE; Rotstein OD; Christou NV; Dellinger EP; Tellado JM; Malafaia O; Fernandez A; Choe KA; Carides A; Satishchandran V; Teppler H;
Ann Surg; 2003 Feb; 237(2):235-45. PubMed ID: 12560782
[TBL] [Abstract][Full Text] [Related]
4. Ertapenem versus piperacillin-tazobactam for treatment of mixed anaerobic complicated intra-abdominal, complicated skin and skin structure, and acute pelvic infections.
Tellado J; Woods GL; Gesser R; McCarroll K; Teppler H
Surg Infect (Larchmt); 2002; 3(4):303-14. PubMed ID: 12697078
[TBL] [Abstract][Full Text] [Related]
5. Ertapenem versus piperacillin/tazobactam for diabetic foot infections (SIDESTEP): prospective, randomised, controlled, double-blinded, multicentre trial.
Lipsky BA; Armstrong DG; Citron DM; Tice AD; Morgenstern DE; Abramson MA
Lancet; 2005 Nov; 366(9498):1695-703. PubMed ID: 16291062
[TBL] [Abstract][Full Text] [Related]
6. Impact of a Dynamic Microbiological Environment on the Clinical Efficacy of Ertapenem and Piperacillin/Tazobactam in the Treatment of Complicated Community-Acquired Intra-Abdominal Infection in Spain: A Cost-Consequence Analysis.
Grau S; Lozano V; Valladares A; Cavanillas R; Xie Y; Nocea G
Appl Health Econ Health Policy; 2015 Aug; 13(4):369-79. PubMed ID: 25761545
[TBL] [Abstract][Full Text] [Related]
7. Ertapenem versus piperacillin/tazobactam for diabetic foot infections in China: a Phase 3, multicentre, randomized, double-blind, active-controlled, non-inferiority trial.
Xu ZR; Ran XW; Xian Y; Yan XD; Yuan GY; Mu SM; Shen JF; Zhang BS; Gan WJ; Wang J
J Antimicrob Chemother; 2016 Jun; 71(6):1688-96. PubMed ID: 26888908
[TBL] [Abstract][Full Text] [Related]
8. Treatment of polymicrobial infections: post hoc analysis of three trials comparing ertapenem and piperacillin-tazobactam.
Solomkin J; Teppler H; Graham DR; Gesser RM; Meibohm AR; Roy S; Woods GL
J Antimicrob Chemother; 2004 Jun; 53 Suppl 2():ii51-7. PubMed ID: 15150183
[TBL] [Abstract][Full Text] [Related]
9. Management of complicated appendicitis and comparison of outcome with other primary sites of intra-abdominal infection: results of a trial comparing ertapenem and piperacillin-tazobactam.
Teppler H; Meibohm AR; Woods GL
J Chemother; 2004 Feb; 16(1):62-9. PubMed ID: 15078001
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of ertapenem versus piperacillin-tazobactam for the treatment of intra-abdominal infections requiring surgical intervention.
Dela Pena AS; Asperger W; Köckerling F; Raz R; Kafka R; Warren B; Shivaprakash M; Vrijens F; Giezek H; DiNubile MJ; Chan CY;
J Gastrointest Surg; 2006 Apr; 10(4):567-74. PubMed ID: 16627223
[TBL] [Abstract][Full Text] [Related]
11. Acquisition of resistant bowel flora during a double-blind randomized clinical trial of ertapenem versus piperacillin-tazobactam therapy for intraabdominal infections.
DiNubile MJ; Chow JW; Satishchandran V; Polis A; Motyl MR; Abramson MA; Teppler H
Antimicrob Agents Chemother; 2005 Aug; 49(8):3217-21. PubMed ID: 16048928
[TBL] [Abstract][Full Text] [Related]
12. Ertapenem versus piperacillin/tazobactam for the treatment of complicated infections: a meta-analysis of randomized controlled trials.
An MM; Zou Z; Shen H; Zhang JD; Chen ML; Liu P; Wang R; Jiang YY
BMC Infect Dis; 2009 Dec; 9():193. PubMed ID: 19951447
[TBL] [Abstract][Full Text] [Related]
13. Ertapenem once a day versus piperacillin-tazobactam every 6 hours for treatment of acute pelvic infections: a prospective, multicenter, randomized, double-blind study.
Roy S; Higareda I; Angel-Muller E; Ismail M; Hague C; Adeyi B; Woods GL; Teppler H;
Infect Dis Obstet Gynecol; 2003; 11(1):27-37. PubMed ID: 12839630
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of ertapenem in the treatment of serious infections caused by Enterobacteriaceae: analysis of pooled clinical trial data.
Gesser RM; McCarroll K; Teppler H; Woods GL
J Antimicrob Chemother; 2003 May; 51(5):1253-60. PubMed ID: 12697633
[TBL] [Abstract][Full Text] [Related]
15. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).
Solomkin J; Hershberger E; Miller B; Popejoy M; Friedland I; Steenbergen J; Yoon M; Collins S; Yuan G; Barie PS; Eckmann C
Clin Infect Dis; 2015 May; 60(10):1462-71. PubMed ID: 25670823
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness evaluation of ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections accounting for antibiotic resistance.
Jansen JP; Kumar R; Carmeli Y
Value Health; 2009; 12(2):234-44. PubMed ID: 20667059
[TBL] [Abstract][Full Text] [Related]
17. Ertapenem once daily versus piperacillin-tazobactam 4 times per day for treatment of complicated skin and skin-structure infections in adults: results of a prospective, randomized, double-blind multicenter study.
Graham DR; Lucasti C; Malafaia O; Nichols RL; Holtom P; Perez NQ; McAdams A; Woods GL; Ceesay TP; Gesser R
Clin Infect Dis; 2002 Jun; 34(11):1460-8. PubMed ID: 12015692
[TBL] [Abstract][Full Text] [Related]
18. [New Beta-lactam agent in the treatment of intra-abdominal sepsis: double blind and randomized stage III study of ertapenem versus piperacillin/tazobactam].
Barboza E; Solomkin J; Goldstein EJ; del Castillo M; Alvarado R; Barboza A; Teppler H
Rev Gastroenterol Peru; 2003; 23(3):192-8. PubMed ID: 14532920
[TBL] [Abstract][Full Text] [Related]
19. Surgical infections with enterococcus: outcome in patients treated with ertapenem versus piperacillin-tazobactam.
Teppler H; McCarroll K; Gesser RM; Woods GL
Surg Infect (Larchmt); 2002; 3(4):337-49. PubMed ID: 12697080
[TBL] [Abstract][Full Text] [Related]
20. Pharmacoeconomics of ciprofloxacin plus metronidazole vs. piperacillin-tazobactam for complicated intra-abdominal infections.
Paladino JA; Gilliland-Johnson KK; Adelman MH; Cohn SM
Surg Infect (Larchmt); 2008 Jun; 9(3):325-33. PubMed ID: 18570574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
